Evidence for Stem Cells in the Peripheral Blood of Mice

Goodman, Joel W.; Hodgson, George

doi:10.1182/blood.v19.6.702.702

Cited by 405 publications

(81 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5,6 Mononuclear hematopoietic progenitor cells are present at low concentrations in the peripheral blood of a variety of species. [7][8][9] Development of techniques to both increase peripheral blood mononuclear cell (PBMC) counts using cloned hematopoietic cytokines 10,11 and collect large numbers of these cells via centrifugation using continuous-flow blood separators increased yields. [12][13][14] In dogs, both autologous 15,16 and allogeneic 17 PBMC grafts were able to reconstitute normal hematopoiesis after lethal bone marrow ablation.…”

mentioning

confidence: 99%

Collection of Peripheral Blood CD34+ Progenitor Cells from Healthy Dogs and Dogs Diagnosed with Lymphoproliferative Diseases Using a Baxter‐Fenwal CS‐3000 Plus Blood Cell Separator

Suter

2011

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Canine peripheral blood mononuclear cell (PBMC) apheresis using a Baxter‐Fenwal CS‐3000 Plus automated blood cell separator has not been reported. Objective To determine the feasibility and safety of using a CS‐3000 Plus blood cell separator with a small volume separation container holder (SVSCH) and small volume collection chamber (SVCC) to harvest canine PBMCs from dogs weighing <50 kg. Animals Eight healthy mongrel dogs and 11 client‐owned dogs in clinical remission for lymphoproliferative diseases (LPD). Methods In this prospective study, aphereses were performed using a Baxter‐Fenwal CS‐3000 Plus blood cell separator, with or without recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) treatment. Results Aphereses from 6 healthy dogs given rhG‐CSF yielded an average of 1.1 × 107 ± 8.2 × 106 CD34+ cells/kg. Aphereses from LPD dogs given rhG‐CSF yielded an average of 5.4 × 106 ± 3.25 × 106 CD34+ cells/kg (P = .17). Higher hematocrit in both groups of dogs receiving rhG‐CSF correlated with an increased number of CD34+ cells/kg harvested (healthy, P = .04; LPD, P = .05). Apheresis was well tolerated by all dogs. Conclusions and Clinical Importance Canine PBMC apheresis using the Baxter‐Fenwal CS‐3000 Plus cell separator with an SVSCH and SVCC is a feasible and safe option for harvesting an adequate number of CD34+ peripheral blood progenitor cells from dogs weighing ≥17 kg for hematopoietic cell transplantation.

show abstract

mentioning

confidence: 99%

Collection of Peripheral Blood CD34+ Progenitor Cells from Healthy Dogs and Dogs Diagnosed with Lymphoproliferative Diseases Using a Baxter‐Fenwal CS‐3000 Plus Blood Cell Separator

Suter

2011

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Early studies demonstrated that, in the physiological state, hematopoietic stem cells and their committed progenitors were present at low concentrations in the peripheral blood of mice, dogs, baboons, and humans. [49][50][51][52] However, large-scale use of PBMC grafts in human patients with life-threatening hematologic disorders awaited development of techniques to collect large numbers of PBMCs and preclinical validation of PBMC grafting protocols. Leukaphereses have been reported in dogs since 1967 for the purpose of transplanting circulating hematopoietic stem cells and for evaluating granulocyte therapeutic support.…”

mentioning

confidence: 99%

Principles of Peripheral Blood Mononuclear Cell Apheresis in a Preclinical Canine Model of Hematopoietic Cell Transplantation

Lupu

Gooley

Zellmer

et al. 2008

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Preclinical studies of peripheral blood mononuclear cell (PBMC) transplantation conducted in a well-established canine hematopoietic cell transplantation (HCT) model have been successfully translated to human patients over the past 5 decades.Objective: We retrospectively investigated the safety and feasibility of PBMC apheresis in the canine model of HCT by analyzing apheresis parameters, cell yields, and the impacts of donor-related and apheresis-related variables on collection yields and donor stability.Animals: One hundred and twenty dogs that underwent PBMC aphereses were evaluated. Methods: Aphereses were performed with a COBE Spectra blood separator and a central dual-lumen catheter, with or without recombinant canine granulocyte colony-stimulating factor (rcG-CSF) stem cell mobilization.Results: Aphereses from dogs not given rcG-CSF yielded an average volume of 280 AE 42 mL containing an average of 15,086 AE 9,834 leukocytes/mL. Aphereses from dogs given rcG-CSF yielded an average volume of 261 AE 55 mL containing an average of 39,711 AE 24,488 leukocytes/mL. Higher pre-apheresis white blood cell (WBC) counts correlated with higher apheresis WBC yields (R 5 0.50, Po.0001). The correlations of collection time, inlet volume, and collection flow rate on WBC yields were statistically significant but only weak to moderate in magnitude (R 5 0.34, P 5 .0001; R 5 0.38, P 5 .0006; R 5 0.26, P 5 .002, respectively) as were the correlations of collection time and inlet volume on collection volumes (R 5 0.30, P 5 .002; R 5 0.42, Po.0001, respectively). All dogs recovered promptly after PBMC aphereses and catheter removal, without complications.Conclusions and Clinical Importance: These data may be useful for translating PBMC apheresis technology to the field of veterinary oncology for the treatment of dogs with hematologic malignancies.

show abstract

“…HSCs have long been known to be present in peripheral blood; this is most directly demonstrated by the long-term multilineage reconstitution observed in recipients of transferred whole blood. [40][41][42][43] HSCs are not the sole progenitor in the circulation, as more downstream MPPs and LMPPs can be reliably detected in blood as well, though at very low frequencies. 36,38,43 Relatively little is known about the physiologic mechanisms that govern the egress of BM progenitors into the blood.…”

Section: Mobilization Of Bm Progenitors Into Bloodmentioning

confidence: 99%

Hematopoietic progenitor migration to the adult thymus

Zlotoff

Bhandoola

2011

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

While most hematopoietic lineages develop in the bone marrow (BM), T cells uniquely complete their development in the specialized environment of the thymus. Hematopoietic stem cells with long-term self-renewal capacity are not present in the thymus. As a result, continuous T cell development requires that BM-derived progenitors be imported into the thymus throughout adult life. The process of thymic homing begins with the mobilization of progenitors out of the bone marrow, continues with their circulation in the bloodstream, and concludes with their settling in the thymus. This review will discuss each of these steps as they occur in the unirradiated and postirradiation scenarios, focusing on the molecular mechanisms of regulation. Improved knowledge about these early steps in T cell generation may accelerate the development of new therapeutic options in patients with impaired T cell number or function.

show abstract

Evidence for Stem Cells in the Peripheral Blood of Mice

Cited by 405 publications

References 13 publications

Collection of Peripheral Blood CD34+ Progenitor Cells from Healthy Dogs and Dogs Diagnosed with Lymphoproliferative Diseases Using a Baxter‐Fenwal CS‐3000 Plus Blood Cell Separator

Collection of Peripheral Blood CD34+ Progenitor Cells from Healthy Dogs and Dogs Diagnosed with Lymphoproliferative Diseases Using a Baxter‐Fenwal CS‐3000 Plus Blood Cell Separator

Principles of Peripheral Blood Mononuclear Cell Apheresis in a Preclinical Canine Model of Hematopoietic Cell Transplantation

Hematopoietic progenitor migration to the adult thymus

Contact Info

Product

Resources

About